Evaluation of in vitro storage properties of prestorage pooled whole blood–derived platelets suspended in 100 percent plasma and treated with amotosalen and long‐wavelength ultraviolet light

Wagner, Stephen J.; Skripchenko, Andrey; Myrup, Andrew; Awatefe, Helen; Thompson-Montgomery, Dedeene; Moroff, Gary; Carmichael, Patrick; Lin, Lily

doi:10.1111/j.1537-2995.2008.02040.x

Cited by 16 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our hands, INTERCEPT treatment on HPL resulted in a 10% loss of platelets but these data confirmed those reported by Wagner et al (50), and did not affect cell culture behavior.…”

Section: Discussionsupporting

confidence: 82%

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In our hands, INTERCEPT treatment on HPL resulted in a 10% loss of platelets but these data confirmed those reported by Wagner et al (50), and did not affect cell culture behavior.…”

Section: Discussionsupporting

confidence: 82%

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, only when larger contents are analysed in a scatter plot like in Fig. do such correlations become apparent .…”

Section: Discussionmentioning

confidence: 97%

High platelet content can increase storage lesion rates following Intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis

Feys

Devloo²,

Sabot³

et al. 2017

Vox Sanguinis

View full text Add to dashboard Cite

Background Pathogen inactivation methods for platelet concentrates are increasingly being used in blood banks worldwide. In vitro studies have demonstrated its effects on storage lesion, but little routine quality control data on blood banking outcomes have been reported. Materials and MethodsSwirling of distributed products was monitored before and after implementation of Intercept pathogen inactivation. Metabolic parameters pH, glucose and lactic acid were determined in a random cohort of expired pathogen-inactivated products. Storage lesion indicators in apheresis concentrates with premature low swirling were compared to concentrates with normal swirling.Results During validation for implementing Intercept pathogen inactivation, pH and glucose levels decreased faster in apheresis platelet concentrates with high platelet content than with low platelet content or than in pathogen-inactivated pooled buffy coat-derived products. In routine products, glucose exhaustion was more often found in apheresis compared to buffy coat-derived platelet concentrates despite 3-7% more plasma carryover in the former. Annual incidence of premature low swirling increased significantly by 50% following implementation of pathogen inactivation implementation for apheresis but not for pooled buffy coat platelet concentrates. In addition, apheresis concentrates with premature low swirling had a significantly higher median platelet count (5Á0 9 10 11 ) than unaffected products (3Á5 9 10 11 ). ConclusionThe risk of increased storage lesion rates following Intercept pathogen inactivation is higher for apheresis than for buffy coat-derived platelet concentrates, especially when platelet contents are higher than 5Á0 9 10 11 .

show abstract

“…This is done by transferring the treated platelet product through a compound adsorption device (CAD) before storage (Lin et al ., ). The multiple transfer steps, including the CAD incubation, increased the processing time, as well as reducing the platelet yield by up to 10%, as has been previously noted (Al‐Radwan et al ., ; Wagner et al ., ).…”

mentioning

confidence: 97%

In vitro assessment of buffy‐coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system

Johnson

Loh

Kwok

et al. 2013

Transfusion Medicine

View full text Add to dashboard Cite

show abstract

Evaluation of in vitro storage properties of prestorage pooled whole blood–derived platelets suspended in 100 percent plasma and treated with amotosalen and long‐wavelength ultraviolet light

Abstract: PCT of leukoreduced PLT pools of whole blood-derived PLTs in 100 percent plasma maintained adequate PLT in vitro variables through 5 days of storage.

Cited by 16 publications

References 32 publications

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

High platelet content can increase storage lesion rates following Intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis

In vitro assessment of buffy‐coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system

Contact Info

Product

Resources

About